Tumor-suppressive roles of ΔNp63β-miR-205 axis in epithelial–mesenchymal transition of oral squamous cell carcinoma via targeting ZEB1 and ZEB2

Yuma Hashiguchi1 | Shintaro Kawano1 | Yuichi Goto2 | Kaori Yasuda3 | Naoki Kaneko1 | Taiki Sakamoto1 | Ryota Matsubara1 | Teppei Jinno1 | Yasuyuki Maruse1 | Hideaki Tanaka1 | Masahiko Morioka1 | Taichi Hattori1 | Shoichi Tanaka1 | Tamotsu Kiyoshima4 | Seiji Nakamura1

1 Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University, Fukuoka, Japan
2 Maxillofacial Diagnostic and Surgical Science, Department of Oral and Maxillofacial Rehabilitation, Course for Developmental Therapeutics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
3 Cell Innovator, Inc., Venture Business Laboratory of Kyushu University, Fukuoka, Japan
4 Laboratory of Oral Pathology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University, Fukuoka, Japan

Correspondence
Shintaro Kawano, DDS, PhD, Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Email: skawano@dent.kyushu-u.ac.jp

Funding information
Japanese Ministry of Education, Culture, Sports, Science and Technology, Grant numbers: 15K20539, 16H07063, 17K11845, 26463014, 26670869, 26861729

We previously revealed that epithelial-to-mesenchymal transition (EMT) was mediated by ΔNp63β, a splicing variant of ΔNp63, in oral squamous cell carcinoma (OSCC). Recent studies have highlighted the involvement of microRNA (miRNA) in EMT of cancer cells, though the mechanism remains unclear. To identify miRNAs responsible for ΔNp63β-mediated EMT, miRNA microarray analyses were performed by ΔNp63β-overexpression in OSCC cells; SQUU-B, which lacks ΔNp63 expression and displays EMT phenotypes. miRNAs microarray analyses revealed miR-205 was the most up-regulated following ΔNp63β-overexpression. In OSCC cells, miR-205 expression was positively associated with ΔNp63 and negatively with zinc-finger E-box binding homeobox (ZEB) 1 and ZEB2, potential targets of miR-205. miR-205 overexpression by miR-205 mimic transfection into SQUU-B cells led to decreasing ZEB1, ZEB2, and mesenchymal markers, increasing epithelial markers, and reducing cell motilities, suggesting inhibition of EMT phenotype. Interestingly, the results opposite to this phenomenon were obtained by transfection of miR-205 inhibitor into OSCC cells, which express ΔNp63 and miR-205. Furthermore, target protector analyses revealed direct regulation by miR-205 of ZEB1 and ZEB2 expression. These results showed tumor-suppressive roles of ΔNp63β and miR-205 by inhibiting EMT thorough modulating ZEB1 and ZEB2 expression in OSCC.

KEYWORDS
ΔNp63β, cancer, EMT, miRNA, OSCC
INTRODUCTION

Oral squamous cell carcinoma (OSCC) is one of the most common malignancies arising in oral cavity. Recent remarkable advancement of diagnostic modalities and reconstructive surgery led early detection of OSCC and radical operation for advanced cancer. However, the overall survival rate of OSCC patients has not risen satisfactory during last decade because of local aggressiveness and metastasis (Jerez et al., 2010; Massano et al., 2006). Metastasis progresses through multi-step process which includes local cancer invasion, entry into the vasculature followed by the exit of cancer cells from the circulation and colonization at the distal sites (Spano, Heck, De Antonellis, Christofori, & Zollo, 2012; Woodhouse et al., 1997). Therefore, to clarify the molecular mechanism of cancer invasion as a first step of metastasis leads to improve the survival rate of OSCC patients by inhibiting metastasis.

Epithelial-to-mesenchymal transition (EMT) is a biological process characterized by biochemical and morphological changes that enable epithelial cell to acquire a mesenchymal cell phenotype during embryonic development and wound healing (Hay, 1995). Following EMT, migratory capacity is enhanced and production of extracellular matrix is greatly increased (Thiery, 2002). Recent reports have revealed that EMT is involved in cancer invasion and progression (Potenta, Zeisberg, & Kalluri, 2008). It has also been demonstrated that Snail, a zinc finger transcription factor involved in cancer cell EMT, directly suppresses E-cadherin expression (Battle et al., 2000). Other zinc finger transcription factors, including zinc finger E-box binding homeobox (ZEB) 1, Slug and Twist have also been reported to repress E-cadherin expression and induce EMT (Adhikary et al., 2014; Sarrio et al., 2008; Yang et al., 2004). Previously, we have also studied on the association of p63 gene, a homolog of the p53 tumor suppressor gene, with EMT in OSCC cells (Goto et al., 2014; Matsubara et al., 2011). p63 has two different promoter domains that generate two protein isoforms, TAp63 and ΔNp63 (Levine, Tomasini, McKeon, Mak, & Melino, 2011). In addition, each isoform yields three isotypes (α, β, and γ) generated by alternative splicing of the p63 COOH terminus (Yang et al., 2004). TAp63 transactivates p53 target genes that induce apoptosis by inhibiting cell proliferation in response to exposure to DNA-damaging agents (Crook, Nicholls, Brooks, O’Nions, & Allday, 2000). Conversely, ΔNp63 exerts dominant-negative activities against TAp63 and p53, and is thus considered an oncoprotein (Higashikawa et al., 2009). Our previous data demonstrated that down-regulation of ΔNp63 accompanied with EMT and that re-expression of ΔNp63β by stable cDNA transfection in OSCC cell lines reverted the EMT phenotype (Goto et al., 2014). However, the detail mechanisms of ΔNp63β-mediated EMT remain to be unclear.

microRNAs (miRNAs) are small non-coding RNAs of 20–23 nucleotides in length that have a crucial role in post-transcriptional regulation of gene expression by binding to a target site in the 3′-UTR of target miRNAs (Ambros, 2004). miRNAs are reported to regulate the expression of genes that mediate critical processes in tumorigenesis, such as differentiation, cell cycle regulation, apoptosis, and invasion (Esquela-Kerscher & Slack, 2006; Farazi, Hoell, Morozov, & Tuschl, 2013). Recent studies have shown that several miRNAs are also involved in EMT process of human cancer by targeting EMT-related transcription factors (Gregory, Bracken, Bert, & Goodall, 2008; Zaravinos, 2015). We thus sought to identify responsible miRNA associated with ΔNp63β-mediated EMT using miRNA microarray analyses in this study. As samples for miRNA microarray, we used two clones established from an OSCC cell line SQUU-B, which lacks ΔNp63 expression and displays EMT phenotypes. One is SQUU-BO cell overexpressing ΔNp63β, and another is SQUU-BC cell transfected with empty vector (Goto et al., 2014). By comparing expression profiles of the two OSCC clones, we focused on miR-205, which is involved in epithelial differentiation (Ryan, Oliveira-Fernandes, & Lavker, 2006), because miR-205 expression was remarkably increased in SQUU-BO cells. Herein, we present some evidences that miR-205 is possibly involved in ΔNp63β-mediated EMT.

MATERIALS AND METHODS

2.1 Cell cultures experiments

This study was approved by the Ethics Committee of Kyushu University hospital (IRB serial number: 27–362). Seven OSCC cell lines (HSC-2, HSC-3, SQUU-A, SQUU-B, SQUU-BO, SQUU-BC, and SAS) and a keratinocyte cell (HaCaT) were used in this study. SQUU-A and SQUU-B cells were previously established from the same patient with recurrent tongue carcinoma by orthotopic implantation. SQUU-B cells show histologically invasive growth and have high metastatic potential (86.7% incidence of cervical lymph node metastasis), whereas SQUU-A cells demonstrate expansive growth and have low metastatic ability (Morifuji, Taniguchi, Sakai, Nakabeppu, & Ohishi, 2000). SQUU-BO cells were generated by transfection with ΔNp63β expression vector, as previously described (Goto et al., 2014). All cell lines were maintained in a humidified atmosphere of 5% CO₂ at 37 °C, and cultured in Dulbecco’s modified Eagle’s medium (DMEM)/F-12 (Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) and 100 units/ml penicillin/streptomycin.

2.2 miRNA microarray analyses

To find miRNA associated with ΔNp63β-mediated EMT, total RNA including miRNA was extracted from SQUU-BO and SQUU-BC cells. The 100 ng of total RNA from each sample was labeled using FlashTag™ Biotin HSR RNA Labeling Kit (Affymetrix, Santa Clara, CA), and hybridized to a Affymetrix GeneChip® miRNA 4.0 Array according to the manufacturer’s instructions. All hybridized microarray slides were scanned using an Affymetrix scanner. Relative hybridization intensities and background hybridization values were calculated using Affymetrix Expression Console™.

2.3 Data analyses and filter criteria

We processed the raw CEL files for gene-level analysis with median polish summarization and quantile normalization by Affymetrix® Transcriptome Analysis Console Software, and obtained normalized intensity values. To identify up or down-regulated genes, we calculated ratios (non-log scaled fold-change) from the normalized intensities of
each gene for comparisons between SQUU-BC and SQUU-BO cells. Then we established criteria for regulated genes with average signal levels of either more than 100: (up-regulated genes) ratio ≥2.0-fold, (down-regulated genes) ratio ≤0.5. In addition, prediction of target genes of miRNAs was performed using miRTarBase (http://mirtarbase.mbc.nctu.edu.tw; September 2015 released) (Chou et al., 2016) and MicroCosm (http://www.ebi.ac.uk/microcosm) (Griffiths-Jones, Saini, van Dongen, & Enright, 2008) software which is a comprehensive resource of miRNA targets and expression profiles.

### 2.4 RNA extraction and complementary DNA (cDNA) synthesis

For mRNA analysis, total RNA was extracted from cultured cells using TRIzol reagent (Invitrogen, Carlsbad, CA). The amount of RNA extracted from each sample was measured spectrophotometrically (NANO DROP 1000, Thermo Fisher Scientific, Waltham, MA). Two micrograms of the total RNA preparation was then used to synthesize cDNA. Briefly, RNA was incubated for 15 min at 42 °C with 35 units/µl of recombinant RNase inhibitor (Nacalai Tesque, Kyoto, Japan), 1.0 µl of 50 µM random hexamers (Invitrogen), 2.0 µl of each 2.0 mM dNTP (Toyobo, Osaka, Japan), and 50 units/µl of Murine leukemia virus (MuLV) reverse transcriptase (Applied Biosystems, Foster City, CA). For miRNA analysis, total RNA was extracted using a mirNeasy Mini Kit (QIAGEN, Hilden, Germany), and reverse transcription was performed using miScript II RT Kit (QIAGEN) according to the manufacturer’s instructions.

### 2.5 Quantitative real-time PCR

Real-time PCR was performed for quantification of gene expression levels, using Brilliant II SYBR Green QPCR Master Mix (Agilent Technologies, Santa Clara, CA). Gene expression levels were quantified using the Real-time PCR System (Mx3000P, Stratagene, San Diego, CA), according to the manufacturer’s instructions. For amplification of specific regions of target genes, the primers used were listed in Table 1. For miRNA detection, real-time PCR was performed with a miScript SYBR Green PCR Kit (QIAGEN). The primers for miRNAs were as follows: miR-205 (hsa-miR-205-5p, MS00003780, QIAGEN), and RNU6B (U6 small nuclear RNA 2, MS00033740, QIAGEN). For relative quantification, the 2^−ΔΔCt method, representing fold changes in the target genes normalized to a reference gene, was used. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and RNU6B were used as the internal control.

### 2.6 Immunocytochemistry

Cultured cells were fixed in 75% methanol and then incubated with each primary antibody. The primary antibodies used were shown in Table 2. Subsequently, the cells were incubated with secondary antibodies conjugated with anti-mouse or rabbit fluorescence-labeled antibody (Alexa Fluor® 488 and 546, Molecular Probes, Eugene, OR; diluted 1:400). The cells were counterstained with DAPI (Vector Laboratories, Burlingame, CA). Fluorescently-labeled cells were observed under a fluorescence microscope (BZ-9000, KEYENCE, Tokyo, Japan).

### 2.7 Western blotting

Cell lysate was denatured, separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), and transferred onto

---

### TABLE 1 Primers used in this study

| mRNA | Size (bp) | Sequence |
|------|-----------|----------|
| ΔNp63 | 117       | Forward: TGCCGAGCTCAAATTAGTGAG <br> Reverse: TGGCCGTGCTGTTATA |
| ZEB1  | 118       | Forward: AAGACATGGACGAGCTTGG <br> Reverse: TGGCTTCTTCCACTGTAATTC |
| ZEB2  | 211       | Forward: AGCGGAAAACAGGTATTC <br> Reverse: GGTCTTTTCTCGTGTTTG |
| E-cadherin | 196     | Forward: TGTCTTCCAAGAAACTCTG <br> Reverse: AGGGAAACTCTCCTCGTCA |
| CK19  | 174       | Forward: TCAGGACCAAATTTTGAGACG <br> Reverse: TGATTTCTCTCTCAGTTGT |
| Vimentin | 196      | Forward: TGGCCCTTAAGGAACAAATG <br> Reverse: CTTAATGCTAAGGGCCATCT |
| N-cadherin | 163     | Forward: TGAAAGGAGTCAGCAAAGTTGA <br> Reverse: TCCAGACCTGATCTGACAAGC |
| Fibronectin | 170      | Forward: GCAAGGCTCACAGCTGAGAAG <br> Reverse: GTCTGATCGTGGACATCATT |
| GAPDH | 104       | Forward: ATACGCAATGCTCCCTGAC <br> Reverse: ATGGCTGACGTGTGCTCAT |

---

### TABLE 2 Primary antibodies used in this study

| Antibodies | Application | Dilution |
|------------|-------------|----------|
| Polyclonal rabbit anti-human ZEB1 antibodies (Atlas Antibodies AB, Stockholm, Sweden) | ICC | 1/200 |
| Polyclonal rabbit anti-human ZEB2 antibodies (Abcam, Cambridge, UK) | ICC | 1/200 |
| Monoclonal mouse anti-human E-cadherin antibody (BD biosciences, Franklin Lakes, NJ) | ICC | 1/200 |
| Monoclonal rabbit anti-human β-actin antibody (C4, Santa Cruz Biotechnology, Dallas, TX) | WB | 1/1000 |
| Monoclonal rabbit anti-human ZEB1 antibody (Cell Signaling Technology, Danvers, MA) | WB | 1/500 |
| Monoclonal rabbit anti-human ZEB2 antibodies (Merck Millipore, Darmstadt, Germany) | WB | 1/2000 |

ICC, immunocytochemical staining; WB, Western blotting.
a polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA). The PVDF membrane was incubated with blocking buffer and then incubated separately with primary antibodies at 4 °C overnight, followed by horseradish peroxidase (HRP)-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA) at room temperature for 1 hr. The primary antibodies used were shown in Table 2. The detection of specific proteins was carried out with enhanced chemiluminescence reagents (Chemi-Lumi One Super, Nacalai Tesque) and visualized using ImageQuant LAS 4000 (Fuji Film, Tokyo, Japan). β-actin was used as a positive control.

2.8 | Small interfering RNA (siRNA) transfection

The sequences of the siRNAs used in this study were as follows: ΔNp63 siRNA, 5ʹ-GGACAGCAGATTTGATCAATT-3ʹ, scrambled siRNA, 5ʹ-CAGTGGCGTTTGGACTGG-3ʹ (Sigma–Aldrich, St. Louis, MO). Cells were seeded at 2 × 10⁵ cells per well in six-well plates and transfected with siRNAs using Lipofectamine RNAiMAX reagent (Invitrogen). Extraction of RNA was performed 48 hr after transfection.

2.9 | miRNA mimic and inhibitor transfection

Cells were seeded at 2 × 10⁵ cells per well in six-well plates and transfected with miScript miR-205 mimic (Syn-hsa-miR-205-5p: MSY0000266, QIAGEN), miScript miR-205 inhibitor (Anti-hsa-miR-205-5p: MIN0000266, QIAGEN), or each control miRNA (QIAGEN). All miRNA mimic, miRNA inhibitor, and control miRNA were transiently transfected into cells using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s instructions. Extraction of RNA and proteins were performed 48 hr and 72 hr after transfection, respectively.

2.10 | Target inhibition analyses of miRNA

We predicted the miR-205-binding sites in the 3′-UTR of target gene by TargetScan (http://www.targetscan.org; August 2010 released) software (Agarwal, Bell, Nam, & Bartel, 2015; Lewis et al., 2005), and the specific complimentary sequence for the target site was synthesized using miScript Target Protector (QIAGEN). miR-205 mimic was co-transfected with the target or control protector in the SQUU-B cells according to the manufacturer’s instructions. At 72 hr after transfection, cells were harvested for protein extraction.

2.11 | Wound healing assay

Cells were seeded in 24-well culture dishes and transfected. After 48 hr of the transfection, a wound was incised with a pipette tip in the central area of the confluent culture on the dishes. In order to inhibit cell proliferation, mitomycin C was added to cell cultures at 10 µg/ml for 2 hr after scratching. Detached cells were removed carefully with PBS and migration of cells into the wound areas was observed using a phase-contrast microscope (CKX41 NB-31PHP, Olympus, Tokyo, Japan). The area reduction rates were then calculated.

2.12 | Matrigel™ invasion assay

Cells were seeded at a density of 2 × 10⁵/well on 60-mm dishes, and then the cells were transfected with miR-205 mimic, miR-205 inhibitor, or control miRNA. After 48 hr, cells were loaded in the upper well of the BioCoat™ Matrigel™ invasion chambers (BD Biosciences, Franklin Lakes, NJ) and equal number of the control inserts (BD Biosciences). The cells were incubated for 22 hr and then the invaded cells on the outside of the inserts were visualized using hematoxylin and eosin (HE). The number of invaded cells was counted under a light fluorescence (BZ-9000, KEYENCE). The evaluation of invasion was carried out by percent invasion. The percent invasion was calculated as follows: (mean of number of cells invading through Matrigel™ insert membrane per mean of number of cells migrating through control insert membrane) × 100 (%).

2.13 | Water-soluble tetrazolium (WST)-8 cell proliferation assay

Cell proliferation assays were performed using the Cell Count Reagent SF (Nacalai Tesque), according to the manufacturer’s instructions. Cells were seeded at a density of 2 × 10⁵/well on 60-mm dishes, and then the cells were transfected with miR-205 mimic, miR-205 inhibitor, or control miRNA. After 48 hr, the transfected cells were replaced 2.0 × 10³ cells/well into 96-well plates. After 12 hr of incubation, 10 µl of premixed reagent was added to each well. The plates were further incubated for 2 hr, and absorbance at 450 nm was then measured using a microplate reader (MULTISKAN FC, Thermo Fisher Scientific).

2.14 | Statistical analyses

All statistical analyses were performed with JMP software version 11 (SAS Institute, Tokyo, Japan). The Mann–Whitney U-test was also used to compare relative mRNA and miRNA expression levels by real-time PCR methods. It was also used to assess the significance of the differences between each group in the wound healing assay, cell proliferation assay, and invasion assay. A p-value of less than 0.05 was considered statistically significant.

3 | RESULTS

3.1 | Identification of the miRNAs involved in ΔNp63β-mediated EMT in OSCC cells

To identify the responsible miRNAs involved in ΔNp63β-mediated EMT, miRNA microarray analyses were performed by using SQUU-BC and SQUU-BO cells. miRNA microarray analyses revealed that 16 miRNAs were significantly up-regulated and 12 miRNAs were down-regulated in SQUU-BO cells compared with SQUU-BC cells among 6599 miRNAs (see Table 3). The heat map and scatterplot showed differentially expressed miRNAs between two clones (Figure 1). In the results of miRNA microarray analyses, miR-205 was remarkably overexpressed in SQUU-BO cells compared with SQUU-BC cells. We thus focused on miR-205 for the potential target involved in ΔNp63β-mediated EMT.
3.2 Expression of miR-205 in OSCC cells

Real-time PCR analyses were performed to examine the expression levels of ΔNp63 and miR-205 in OSCC cell lines. miR-205 expression level was most strongly in the SQUU-A and weakly in the SQUU-B, which lacks ΔNp63 expression (Figure 2a). Furthermore, the expression level of miR-205 was positively correlated with ΔNp63 expression. In the SQUU-BO overexpressing ΔNp63β, miR-205 expression was also higher than that in control cells (Figure 2b). To further investigate the association between miR-205 and ΔNp63 expression, we transfected ΔNp63 siRNA into SQUU-A cells. Following ΔNp63 knockdown, the expression of miR-205 was significantly decreased than that in control cells (Figure 2c).

3.3 Expression of ZEB1 and ZEB2, miR-205 targeting genes, in the OSCC cells

To identify the target genes of miR-205, we used miRTarBase and MicroCosm software and further analyzed. Among the candidate genes targeted by miR-205, we focused on ZEB1 and ZEB2 (SIP1 and ZFHX1B) that have been reported as EMT-related transcription factors (Wong, Gao, & Chan, 2014). ZEB1 and ZEB2 have been shown to directly bind to the E-cadherin promoter and repress its transcription. We thus examined the expression of ZEB1, ZEB2, and E-cadherin in OSCC cells by real-time PCR and Western blot analyses. Compared with SQUU-A cells with high expression levels of miR-205, ZEB1 and ZEB2 expression was stronger in SQUU-B cells, while the expression of E-cadherin was weaker (Figures 3a and 3b). Conversely,
SQUU-BO cells showed the weaker expression of ZEB1 and ZEB2 and stronger expression E-cadherin compared with control cells. (Figures 3c and 3d).

Furthermore, we elucidated the localization of ZEB1, ZEB2, and E-cadherin in OSCC cells by immunocytochemical double staining. The expression of ZEB1 and ZEB2 was observed strongly in the nucleus and slightly in the cytoplasm of SQUU-B cells, but E-cadherin was undetectable. On the other hand, in SQUU-A cells, though strong immunoreactivities for E-cadherin was found, ZEB1 and ZEB2 expression was undetectable (Figure 2e).

3.4 | Effects of miR-205 overexpression on EMT phenotype of OSCC cells

To determine the functional roles of miR-205 in ΔNp63β-mediated EMT, miR-205 mimic was transfected into SQUU-B cells for...
FIGURE 3  Expression of ZEB1, ZEB2, and E-cadherin in the OSCC cells. (a and b) Real-time PCR and Western blot analyses demonstrate that SQUU-B cells with low expression levels of ΔNp63 and miR-205 show higher expression of ZEB1 and ZEB2 and lower expression of E-cadherin compared with SQUU-A cells, which expresses ΔNp63 and miR-205 (Mann–Whitney U-test, *p < 0.05). (c and d) Following ΔNp63 overexpression, expression of ZEB1 and ZEB2 are down-regulated, whereas expression level of E-cadherin is elevated (Mann–Whitney U-test, *p < 0.05). (e) Double staining of ZEB1 or ZEB2 with E-cadherin in OSCC cells by immunocytochemistry. The strong expressions of ZEB1 and ZEB2 are observed mainly in the nuclei of SQUU-B cells, but E-cadherin not found. On the other hand, the expression of E-cadherin is detected in the cellular membrane of SQUU-A cells, but expression of ZEB1 and ZEB2 is undetectable. Green, E-cadherin; Red, ZEB1 or ZEB2. Scale bar; 20 µm
FIGURE 4  Effects of miR-205 mimic transfection in SQUU-B cells. (a and b) Expression of ZEB1 and ZEB2 is decreased and E-cadherin increased in the cells transfected with miR-205 mimic. Up-regulation of CK19 and down-regulation of N-cadherin are also seen (Mann–Whitney U-test, \(*p < 0.05\)). However, there are no significant differences in the expression levels of vimentin and fibronectin. (c) Wound healing assay demonstrates that cell migration capacity is significantly inhibited in miR-205-overexpressing OSCC cells, compared with control cells at 72 hr. (Mann–Whitney U-test, \(*p < 0.05\)). Scale bars; 200 µm. (d) miR-205-overexpressing cells show low invasion ability compared with control cells in Matrigel™ invasion assay (Mann–Whitney U-test, \(*p < 0.05\)). Scale bars; 50 µm. (e) WST-8 assay shows that there is no significant difference in the cell proliferation between miR-205-overexpressing cells and control cells (Mann–Whitney U-test).
FIGURE 5  Effects of miR-205 inhibitor transfection in SQUU-A cells. (a and b) Real-time PCR and Western blot analyses demonstrate that knockdown of miR-205 leads to up-regulation of ZEB1 and ZEB2 and down-regulation of E-cadherin. Up-regulation of vimentin and fibronectin are also observed (Mann–Whitney U-test, * $p < 0.05$). On the other hand, there are no significant differences in CK19 and N-cadherin. (c) Wound healing assay demonstrates that knockdown of miR-205 enhances migration capacity compared with control cells at 72 h (Mann–Whitney U-test, * $p < 0.05$). Scale bars; 200 µm. (d) Matrigel™ invasion assay shows high invasion ability in the cells with transfection of miR-205 inhibitor compared with control cells, though no significant difference is found (Mann–Whitney U-test). Scale bars; 50 µm. (e) WST-8 assay shows no significant difference in cell proliferation between cells with silencing of miR-205 and without (Mann–Whitney U-test)
overexpressing miR-205. As a result of miR-205 overexpression, ZEB1 and ZEB2 were significantly decreased at both the gene and protein levels, while those of E-cadherin were increased (Figures 4a and 4b). Although up-regulation of cytokeratin (CK) 19 and down-regulation of N-cadherin (Figure 4a) were also found, expression of vimentin and fibronectin remained unaffected.

In the wound healing assay and Matrigel™ invasion assay, SQUU-B cells transfected with miR-205 mimic showed significantly lower migration and invasion abilities compared with the control cells (Mann-Whitney U-test, \( p < 0.05 \)) (Figures 4c and 4d). However, in the WST-8 assay, no significant difference in the cell proliferation was observed between the cells with overexpression of miR-205 and without (Figure 4e).

### 3.5 Effects of miR-205 knockdown on EMT phenotype of OSCC cells

We further investigated influences of miR-205 knockdown in OSCC cells by miR-205 inhibitor transfection into SQUU-A cells. Real-time PCR and western blot analyses showed that ZEB1 and ZEB2 expression were elevated, while expression of E-cadherin was decreased following transfection of miR-205 inhibitor (Figure 5a and 5b). Moreover, up-regulation of mesenchymal markers including vimentin and fibronectin were also found (Figure 5a).

In the wound healing assay, migration ability of the SQUU-A cells transfected with miR-205 inhibitor was promoted, compared with the control cells (Figure 5c). In the Matrigel™ invasion assay, the number of invaded cells was increased in the SQUU-A cells with knockdown of miR-205, compared with control cells, though no significant difference was shown (Figure 5d). In the WST-8 assay, knockdown of miR-205 did not affect on the proliferation of SQUU-A cells (Figure 5e).

### 3.6 Interfering of miR-205-binding sites in ZEB1 or ZEB2 mRNA

The results in this study suggested that miR-205 regulates ZEB1 and ZEB2 expression in OSCC cells. However, it remains unclear whether miR-205 directly regulates these expressions. Therefore, we predicted the binding sites of miR-205 in the 3’UTR of ZEB1 and

---

**FIGURE 6** Interfering of miR-205-binding sites in ZEB1 or ZEB2 mRNA. (a) The figure shows miR-205-binding sites in ZEB1 and ZEB2 mRNA 3’-UTR. The specific complimentary sequence for the target site is synthesized for this analysis. (b and c) Western blot analyses shows that co-transfection of miR-205 mimic with each target protector inhibits down-regulation of ZEB1 and ZEB2 protein expression.
ZEB2 mRNA by TargetScan software, generated the single strand RNAs as protectors, and performed target inhibition analyses (Figure 6a). By the co-transfection of miR-205 mimic and ZEB1 or ZEB2 target protector into SQUU-B cells, the expression level of ZEB1 or ZEB2 proteins was recovered, though ZEB1 and ZEB2 expression was decreased when miR-205 mimic and control protector were co-transfected. (Figures 6b and 6c).

4 | DISCUSSION

In our previous study, we showed that down-regulated vimentin and down-regulated E-cadherin expression was found in the oral cancer cells at the invasive front. Interestingly, the vimentin positive rate or the presence of decreased intensity of ΔNp63 was positively associated with the frequencies of metastases and poor prognosis in the OSCC patients (Goto et al., 2014). These results indicated that ΔNp63 down-regulation in cancer cells is associated with mesenchymal phenotype in tumor progression of OSCC. A few studies have demonstrated association between the ΔNp63 expression and EMT in squamous cell carcinoma (SCC). Higashikawa et al. (2007) demonstrated that Snail down-regulated ΔNp63α, the predominant ΔNp63 isoform in SCC, thereby leading to induction of EMT. They also revealed that ΔNp63α regulated the inhibitor of differentiation-3 (Id-3), a dominant negative regulator of E2A that functions as a transcriptional repressor of E-cadherin (Higashikawa et al., 2009). These results suggest that ΔNp63α expression is strongly associated with the acquisition of a mesenchymal phenotype. Similar to these findings, we previously demonstrated that ΔNp63β, a splicing variant of ΔNp63, is associated with the induction of EMT in OSCC (Goto et al., 2014). However, the precise molecular mechanism underlying the ΔNp63β-mediated EMT in OSCC cells remains unclear. Recent studies have highlighted the involvement of miRNA in EMT of cancer cells (Zaravinos, 2015). In this study, we thus focused on miR-205, remarkably increased in OSCC cells overexpressed ΔNp63β by miRNA microarray analyses.

miR-205 is transcribed from the MIR205HG gene that is located in the second intron of LOC642587 locus in chromosome 1 (Lim, Glasner, Yekta, Burge, & Bartel, 2003). It has already reported that miR-205 promotes human epidermal keratinocytes and corneal epithelial keratinocytes via the lipid phosphatase SHIP2 (Yu et al., 2010). On the other hands, growing evidences show that miR-205 plays a key role in a variety of tumors and functions as an oncogene or a tumor suppressor gene determined by the cancer context or its target genes (Qin et al., 2013). In gynecological malignancies, miR-205 was remarkably up-regulated in endometrial carcinoma tissues, and enhance tumor proliferation and invasion (Jin & Liang, 2015). Li et al. (2015) showed miR-205 up-regulation induced cell proliferation and invasion in ovarian cancer. On the other hand, miR-205 exerted tumor-suppressive roles in some kinds of cancers including breast cancer, gastric cancer, and prostate cancer (Majid et al., 2010; Wu, Zhu, & Mo, 2009; Yin et al., 2014). As just described above, expression and functions of miR-205 in cancer is controversial, because no distinct evidence for a role of miR-205 as an oncogenic or tumor-suppressive miRNA has been shown. The present study revealed that miR-205 played a tumor-suppressive role by inhibiting migration and invasion in OSCC.

Previously, several studies demonstrated miR-205 expression and the significance as a biomarker in the head and neck squamous cell carcinoma (HNSCC) (Tran et al., 2007; Kimura et al., 2010). miR-205 was firstly identified as an up-regulated miRNA in HNSCC by microarray analysis (Tran et al., 2007). After that, Kimura et al. (2010) also demonstrated that miR-205 could be a specific biomarker for HNSCC. Although there were a few studies on function of miR-205 in HNSCC, most of these studies reported that miR-205 suppresses oncogenic activities such as anti-apoptosis and proliferation (Kim et al., 2013, 2014). Interestingly, Childs et al. (2009) showed that low-level expression of miR-205 significantly associated with loco-regional recurrence independent of disease severity. They also described that combined low expression levels of miR-205 and let-7d, which target the Ras oncogene, are significantly correlated with poor prognosis in HNSCC. These data indicate close association of low-level miR-205 expression with cancer progression. In this study, miR-205 knockdown led to elevated cell motility in OSCC cells, suggesting that our result may be supportive for Childs’s data.

We further showed that enhancing cell motility by miR-205 knockdown was associated with ΔNp63β-mediated EMT. Recent study demonstrated that loss of ΔNp63 and miR-205 enhanced cell migration and metastasis via targeting expression of ZEB1 in prostate cancer (Tucci et al., 2012). Furthermore, ΔNp63α-mediated expression of miR-205 contributed to the regulation EMT in bladder cancer cells, and that miR-205 prevented EMT through suppression of ZEB1 and ZEB2 (Tran et al., 2013). Matsushima et al. (2011) also reported that miR-205 modulates migration and invasion by regulating ZEB1 expression in esophageal SCC. Using miRNA target prediction algorithms, ErB3, E2F5, ZEB1, ZEB2, and protein kinase Cε have been identified as putative miR-205 targets (Gandellini et al., 2009). In fact, knockdown of miR-205 or ΔNp63 led to up-regulation of ZEB1 and ZEB2 in OSCC cells, and the expression level of ZEB1 or ZEB2 was recovered by the co-transfection of miR-205 mimic and ZEB1 or ZEB2 target protector into SQUU-B cells in this study. Previous studies employing a reporter assay confirmed miR-205 binding to the each 3’-UTR of ZEB1 or ZEB2 (Matsushima et al., 2011: Niu, Shen, Zhang, Zhao, & Lu, 2015). Together, these data demonstrated that miR-205 directly inhibits ZEB1 or ZEB2 in OSCC cells.

As described above, it was revealed that ΔNp63α mediated miR-205 expression in bladder cancer (Tran et al., 2013). In this study, however, the miR-205 expression is regulated by not ΔNp63α but ΔNp63β. Previously, different effects of the three isoforms of ΔNp63 were showed by gene expression profiling of HNSCC cells over-expressing each ΔNp63 isoform (Boldrup, Coates, Gu, & Nylander, 2009). Thereby, ΔNp63β was most efficient activator of gene expression than ΔNp63α and ΔNp63γ despite low expression levels in HNSCC, whereas ΔNp63γ was most effective at repressing gene expression. These results thus indicated that miR-205 expression was induced by both ΔNp63α and ΔNp63β.

In conclusion, we clarify that ΔNp63β regulates miR-205 and that these effects contribute to EMT suppression through inhibiting ZEB1 and ZEB2 expression. To the best of our knowledge, this is the first report that elucidated the association of miR-205 with ΔNp63β-mediated EMT. Elucidating the functions of miR-205 in ΔNp63β-mediated EMT will facilitate the identification of valuable
biomarkers of tumor recurrence and metastasis and the development of novel OSCC treatment.

ACKNOWLEDGMENTS

This work was supported by a Grant-in-Aid (26463014, 17K11845, 26861729, 16K20584, 16H07063, 15K20539, 26670869) from the Japanese Ministry of Education, Culture, Sports, Science and Technology.

CONFLICTS OF INTEREST

All authors declare no conflicts of interest.

ORCID

Yuma Hashiguchi https://orcid.org/0000-0002-4697-0374

REFERENCES

Agarwal, V., Bell, G. W., Nam, J. W., & Bartel, D. P. (2015). Predicting effective microRNA target sites in mammalian mRNAs. Elife, 4. https://doi.org/10.7554/eLife.05005

Adhikary, A., Chakraborty, S., Mazumdar, M., Ghosh, S., Mukherjee, S., Manna, A., … Das, T. (2014). Inhibition of epithelial to mesenchymal transition by E-cadherin up-regulation via repression of slug transcription and inhibition of E-cadherin degradation: Dual role of scaffold/matrix attachment region-binding protein 1 (SMAR1) in breast cancer cells. The Journal of Biological Chemistry, 289(37), 25431–25444.

Ambros, V. (2004). The functions of animal microRNAs. Nature, 431(7006), 350–355.

Battle, E., Sancho, E., Franci, C., Dominguez, D., Monfar, M., Baulida, J., & García De Herreros, A. (2000). The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumor cells. Nature Cell Biology, 2(2), 84–89.

Boldrup, L., Coates, P. J., Gu, X., & Nylander, K. (2009). ΔNp63 isoforms differentially regulate gene expression in squamous cell carcinoma: Identification of Cox-2 as a novel p63 target. The Journal of Pathology, 218(4), 428–436.

Childs, G., Fazzari, M., Kung, G., Kawachi, N., Brandwein-Gensler, M., … Schlecht, N. F. (2009). Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. The American Journal of Pathology, 174(3), 736–745.

Chou, C. H., Chang, N. W., Shrestha, S., Hsu, S. D., Lin, Y. L., Lee, W. H., … Huang, H. D. (2016). MiRtarBase 2016: Updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Research, 44(D1), D239–D247.

Crook, T., Nicholls, J. M., Brooks, L., O’Nions, J., & Allday, M. J. (2000). High level expression of deltaN-p63: A mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene, 19(30), 3439–3444.

Esquela-Kerscher, A., & Slack, F. J. (2006). Oncomirs—microRNAs with a role in cancer. Nature Reviews Cancer, 6(4), 259–269.

Farazi, T. A., Hoell, J. I., Morozov, P., & Tuschi, T. (2013). MicroRNAs in human cancer. Advances in Experimental Medicine and Biology, 774, 1–20.

Gandellini, P., Folini, M., Longoni, N., Pennati, M., Binda, M., Colecchia, M., … Zaffaroni, N. (2009). MiR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsonil. Cancer Research, 69(6), 2287–2295.

Goto, Y., Kawano, S., Matsubara, R., Kiyosue, T., Hirano, M., Jinno, T., … Nakamura, S. (2014). Possible involvement of DeltaNp63 down-regulation in the invasion and metastasis of oral squamous cell carcinoma via induction of a mesenchymal phenotype. Clinical and Experimental Metastasis, 31(3), 293–306.

Gregory, P. A., Bracken, C. P., Bert, A. G., & Goodall, G. J. (2008). MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle (Georgetown, Tex), 7(20), 3112–3118.

Griffiths-Jones, S., Saini, H. K., van Dongen, S., & Enright, A. J. (2008). MiRBase: Tools for microRNA genomics. Nucleic Acids Research, 36(Database issue), D154–D158.

Hay, E. D. (1995). An overview of epithelio-mesenchymal transformation. Acta Anatomica, 154(1), 8–20.

Higashikawa, K., Yoneda, S., Tobiue, K., Saitoh, M., Taki, M., Mitani, Y., … Kamata, N. (2009). DeltaNp63alpha-dependent expression of Id-3 distinctively suppresses the invasiveness of human squamous cell carcinoma. International Journal of Cancer, 124(12), 2837–2844.

Higashikawa, K., Yoneda, S., Tobiue, K., Taki, M., Shigeishi, H., & Kamata, N. (2007). Snail-induced down-regulation of ΔNp63α acquires invasive phenotype of human squamous cell carcinoma. Cancer Research, 67(19), 9207–9213.

Jerjes, W., Upile, T., Petrie, A., Riskalla, A., Hamdoon, Z., Zourvachis, M., … Hopper, C. (2010). Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients. Head & Neck Oncology, 2, 9. https://doi.org/10.1186/1758-3284-2-9.

Jin, C., & Liang, R. (2015). miR-205 promotes epithelial-mesenchymal transition by targeting AKT signaling in endometrial cancer cells. The Journal of Obstetrics and Gynaecology Research, 41(10), 1653–1660.

Kim, J. S., Yu, S. K., Lee, M. H., Park, M. G., Park, E., Kim, S. G., … Kim, D. K. (2013). MicroRNA-205 directly regulates the tumor suppressor, interleukin-24, in human KB oral cancer cells. Molecules and Cells, 35(1), 17–24.

Kim, J. S., Park, S. Y., Lee, S. A., Park, M. G., Yu, S. K., Lee, M. H., … Kim, D. K. (2014). MicroRNA-205 suppresses the oral carcinoma oncogenic activity via down-regulation of Axin-2 in KB human oral cancer cell. Molecular and Cellular Biochemistry, 387(1-2), 71–79.

Kimura, S., Naganuma, S., Susuki, D., Hirono, Y., Yamaguchi, A., Fujiyeda, S., … Itoh, H. (2010). Expression of microRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. Oncology Reports, 23(6), 1625–1633.

Levine, A. J., Tomasini, R., McKeon, F. D., Mak, T. W., & Melino, G. (2011). The p53 family: Guardians of maternal reproduction. Nature Reviews Molecular Cell Biology, 12(4), 259–265.

Li, J., Li, L., Li, Z., Gong, G., Chen, P., Liu, H., … Wu, X. (2015). The role of miR-205 in the VEGF-mediated promotion of human ovarian cancer invasion. Gynecologic Oncology, 137(1), 125–133.

Lim, L. P., Glasner, M. E., Yekta, S., Burge, C. B., & Bartel, D. P. (2003). Vertebrate microRNA genes. Science (New York, NY), 299(5612), 1540.

Matsubara, R., Kawano, S., Kiyosue, T., Goto, Y., Hirano, M., Jinno, T., … Nakamura, S. (2011). Increased DeltaNp63 expression is predictive of malignant transformation in oral epithelial dysplasia and poor prognosis in oral squamous cell carcinoma. International Journal of Oncology, 39(6), 1391–1399.

Majid, S., Dar, A. A., Saini, S., Yamamura, S., Hirata, H., Tanaka, Y., … Dahiya, R. (2010). MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer, 116(24), 5637–5649.

Matsushima, K., Isomoto, H., Yamaguchi, N., Inoue, N., Machida, H., Nakayama, T., … Nakao, K. (2011). MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. Journal of Translational Medicine, 9, 30.

Morifuji, M., Taniguchi, S., Sakai, H., Nakabeppu, Y., & Ohishi, M. (2000). Differential expression of cytokeratin after orthotopic implantation of newly established human tongue cancer cell lines of defined metastatic ability. The American Journal of Pathology, 156(4), 1317–1326.

Niu, K., Shen, W., Zhang, Y., Zhao, Y., & Lu, Y. (2015). MiR-205 promotes motility of ovarian cancer cells via targeting ZEB1. Gene, 574(2), 330–336.
Potenta, S., Zeisberg, E., & Kalluri, R. (2008). The role of endothelial-to-mesenchymal transition in cancer progression. *British Journal of Cancer, 99*(9), 1375–1379.

Qin, A. Y., Zhang, X. W., Liu, L., Yu, J. P., Li, H., Wang, S. Z., …, Cao, S. (2013). MiR-205 in cancer: An angel or a devil? *European Journal of Cell Biology, 92*(2), 54–60.

Ryan, D. G., Oliveira-Fernandes, M., & Lavker, R. M. (2006). MicroRNAs of the mammalian eye display distinct and overlapping tissue specificity. *Molecular Vision, 12*, 1175–1184.

Sarrio, D., Rodriguez-Pinilla, S. M., Hardisson, D., Cano, A., Moreno-Bueno, G., & Palacios, J. (2008). Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. *Cancer Research, 68*(4), 989–997.

Spano, D., Heck, C., De Antonellis, P., Christofori, G., & Zollo, M. (2012). Molecular networks that regulate cancer metastasis. *Seminars in Cancer Biology, 22*(3), 234–249.

Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. *Nature Reviews Cancer, 2*(6), 442–454.

Tran, M. N., Choi, W., Wszolek, M. F., Navai, N., Lee, I. L., Nitti, G., …, McConkey, D. J. (2013). The p63 protein isoform ΔNp63alpha inhibits epithelial-mesenchymal transition in human bladder cancer cells: Role of MiR-205. *The Journal of Biological Chemistry, 288*(5), 3275–3288.

Tran, N., McLean, T., Zhang, X., Zhao, C. J., Thomson, J. M., O’Brien, C., & Rose, B. (2007). microRNA expression profiles in head and neck cancer cell lines. *Biochemical and Biophysical Research Communications, 358*(1), 12–17.

Tucci, P., Agostini, M., Grespi, F., Markert, E. K., Terrinoni, A., Vousden, K. H., …, Melino, G. (2012). Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America, 109*(38), 15312–15317.

Wong, T. S., Gao, W., & Chan, J. Y. (2014). Transcription regulation of E-cadherin by zinc finger E-box binding homeobox proteins in solid tumors. *BioMed Research International, 2014*, 921564.

Wu, H., Zhu, S., & Mo, Y. Y. (2009). Suppression of cell growth and invasion by miR-205 in breast cancer. *Cell Research, 19*(4), 439–448.

Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., …, Weinberg, R. A. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. *Cell, 117*(7), 927–939.

Yin, W. Z., Li, F., Zhang, L., Ren, X. P., Zhang, N., & Wen, J. F. (2014). Down-regulation of MicroRNA-205 promotes gastric cancer cell proliferation. *European Review for Medical and Pharmacological Sciences, 18*(7), 1027–1032.

Yu, J., Peng, H., Ruan, Q., Fatima, A., Gsetsios, S., & Lavker, R. M. (2010). MicroRNA-205 promotes keratinocyte migration via the lipid phosphatase SHIP2. *Official Publication of the Federation of American Societies for Experimental Biology, 24*(10), 3950–3959.

Zaravinos, A. (2015). The regulatory role of MicroRNAs in EMT and cancer. *Journal of Oncology, 2015*, 865816.

How to cite this article: Hashiguchi Y, Kawano S, Goto Y, et al. Tumor-suppressive roles of ΔNp63β-miR-205 axis in epithelial-mesenchymal transition of oral squamous cell carcinoma via targeting ZEB1 and ZEB2. *J Cell Physiol*. 2018;233:6565–6577. [https://doi.org/10.1002/jcp.26267](https://doi.org/10.1002/jcp.26267)